rs375168720
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_015214.3(DDHD2):c.1978G>C(p.Asp660His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000133 in 1,614,104 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00014 ( 0 hom. )
Consequence
DDHD2
NM_015214.3 missense
NM_015214.3 missense
Scores
12
6
1
Clinical Significance
Conservation
PhyloP100: 9.90
Genes affected
DDHD2 (HGNC:29106): (DDHD domain containing 2) This gene encodes a phospholipase enzyme containing sterile-alpha-motif (SAM), WWE, and DDHD domains. This protein participates in membrane trafficking between the endoplastic reticulum and the Golgi body. Mutations in this gene can cause autosomal recessive spastic paraplegia 54. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.921
PP5
Variant 8-38253642-G-C is Pathogenic according to our data. Variant chr8-38253642-G-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 39679.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-38253642-G-C is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DDHD2 | NM_015214.3 | c.1978G>C | p.Asp660His | missense_variant | 16/18 | ENST00000397166.7 | NP_056029.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DDHD2 | ENST00000397166.7 | c.1978G>C | p.Asp660His | missense_variant | 16/18 | 2 | NM_015214.3 | ENSP00000380352 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152206Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
10
AN:
152206
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000597 AC: 15AN: 251466Hom.: 0 AF XY: 0.0000662 AC XY: 9AN XY: 135908
GnomAD3 exomes
AF:
AC:
15
AN:
251466
Hom.:
AF XY:
AC XY:
9
AN XY:
135908
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000140 AC: 204AN: 1461780Hom.: 0 Cov.: 31 AF XY: 0.000117 AC XY: 85AN XY: 727192
GnomAD4 exome
AF:
AC:
204
AN:
1461780
Hom.:
Cov.:
31
AF XY:
AC XY:
85
AN XY:
727192
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000656 AC: 10AN: 152324Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74486
GnomAD4 genome
AF:
AC:
10
AN:
152324
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
74486
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
3
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
10
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hereditary spastic paraplegia 54 Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Consultorio y Laboratorio de Neurogenética, Hospital JM Ramos Mejia | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Paris Brain Institute, Inserm - ICM | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 07, 2012 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2016 | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PS3,PM2,PP3,PP5. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 07, 2023 | Variant summary: DDHD2 c.1978G>C (p.Asp660His) results in a non-conservative amino acid change located in the DDHD domain (IPR004177) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6e-05 in 251466 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1978G>C has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Hereditary Spastic Paraplegia 54, and the variant was shown to segregate with disease in related individuals (e.g., Schuurs-Hoeijmakers_2012, Citterio_2015). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 24337409, 23176823). Six ClinVar submitters (evaluation after 2014) have cited the variant, and all submitters classified the variant as pathogenic (n = 4) or likely pathogenic (n = 2). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | May 30, 2022 | - - |
Pathogenic, criteria provided, single submitter | research | University of Science and Technology Houari Boumediene, Laboratory of Molecular and Cellular Biology (LBCM) | Apr 22, 2024 | This missense variant leads to the substitution of a highly conserved aspartic acid (found in 12 species) within the DDHD domain of the DDHD2 protein with histidine. Amino acid alignments were generated using Alamut® Visual v.2.15 software (Interactive Biosoftware, SOPHiA GENETICS). This variant is predicted to be disease-causing by standard in silico prediction tools (CADD, SIFT, PolyPhen-2, and MutationTaster). ClinVar contains an entry for this variant (Variation ID: 39679), it’s classified as pathogenic. This variant is not reported in the 1000 Genomes Project but is present at a low frequency in the gnomAD database [AF = 6.1e-5]. Complete co-segregation between the variant allele and the disease distribution was observed in the patients’ family. This variant was identified in the homozygous state in two affected siblings and was present in the heterozygous state in the unaffected parents. This variant is associated with the following publications: (PMID: 23176823, 24337409, 24517879, 30564185, 31302745, 25417924) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 09, 2024 | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 660 of the DDHD2 protein (p.Asp660His). This variant is present in population databases (rs375168720, gnomAD 0.01%). This missense change has been observed in individual(s) with hereditary spastic paraplegia with thin corpus callosum (PMID: 23176823, 24337409, 24517879). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 39679). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DDHD2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects DDHD2 function (PMID: 25417924). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 25, 2022 | Published functional studies demonstrate a damaging effect; the D660H variant demonstrates a reduction in phospholipase A1 activity (Doi et al., 2014); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 33084218, 25417924, 23176823, 24337409, 24517879, 31302745, 27535533) - |
Generalized epilepsy;C0028754:Obesity;C0557874:Global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Claritas Genomics | Nov 28, 2016 | The c.1978G>C (p.Asp660His) missense variant in the DDHD2 gene is previously reported in the literature and is expected to be causative of hereditary spastic paraplegia when present in the homozygous or compound heterozygous state. DDHD2 encodes a protein that makes up a subunit of the enzyme phospholipase A1 (PLA1). This variant has been reported in multiple affected individuals in the compound heterozygous or homozygous state and has been shown to segregate with disease in families. In vitro functional studies on cell lines with this variant demonstrated significantly reduced PLA1 activity when compared to that of wild type cell lines. This variant involves a highly conserved nucleotide and amino acid, and it is predicted to be damaging by PolyPhen-2, SIFT, and MutationTaster. Therefore, based on prior reports in the literature and functional evidence, this variant is classified as pathogenic. - |
Hereditary spastic paraplegia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | May 17, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;D;.;D;D
Eigen
Uncertain
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;M;.;.;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;D;D
Sift4G
Pathogenic
D;D;D;D;D
Polyphen
D;D;.;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at